Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation

Daisuke Hayakawa1,2, Fumiyuki Takahashi1,2, Yoichiro Mitsuishi1,2, Ken Tajima1,2, Moulid Hidayat1,2, Wira Winardi1,2, Hiroaki Ihara1,2, Koichiro Kanamori1,2, Naohisa Matsumoto1,2, Tetsuhiko Asao1,2, Ryo Ko1,2, Takehito Shukuya1,2, Kazuya Takamochi3, Takuo Hayashi4, Yoshiyuki Suehara5, Ikuko Takeda Nakamura1,6, Toshihide Ueno6, Shinji Kohsaka6, Hiroyuki Mano6 & Kazuhisa Takahashi1,2

1 Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan
2 Research Institute for Diseases of Old Ages, Juntendo University, Graduate School of Medicine, Tokyo, Japan
3 Department of General Thoracic Surgery, Juntendo University, Graduate School of Medicine, Tokyo, Japan
4 Department of Human Pathology, Juntendo University, Graduate School of Medicine, Tokyo, Japan
5 Department of Orthopedic Surgery, Juntendo University, Graduate School of Medicine, Tokyo, Japan
6 Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan

Keywords
EGFR-TKI; IGF1R; NSCLC; osimertinib; resistance.

Correspondence
Daisuke Hayakawa, Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan
Tel: +81 3 5802 1063
Fax: +81 3 5802 1617
Email: dhayaka@juntendo.ac.jp

Received: 5 October 2019; Accepted: 4 November 2019.
doi: 10.1111/1759-7714.13255

Thoracic Cancer 11 (2020) 140–149 © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Abstract
Background: Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance to osimertinib is inevitable.

Methods: We established osimertinib-resistant cells (PC9/T790M/AZDR and H1975/AZDR) derived from EGFR-mutant NSCLC cells harboring T790M mutation, and investigated the mechanism of acquired resistance to osimertinib by whole-exome sequencing and multiple phospho-receptor tyrosine kinase (RTK) array. A tumor specimen from an EGFR-mutant NSCLC patient with acquired resistance to osimertinib was also subjected to immunohistochemical analysis.

Results: Whole-exome sequencing analysis demonstrated that genetic alterations, such as acquisition of EGFR C797S, loss of T790M mutation, MET amplification, or mutated KRAS, MEK, BRAF, PIK3CA, were not detected. Analysis of phospho-RTK array revealed that insulin-like growth factor-1 receptor (IGF1R) was activated in PC9/T790M/AZDR and H1975/AZDR cells. Knockdown of IGF1R by siRNA as well as inhibition of IGF1R activation by linstinib (IGF1R inhibitor) significantly restored the sensitivity to osimertinib. Immunohistochemical analysis revealed that the expression level of phosphorylated IGF1R was higher in the tumor specimen from the EGFR-mutant NSCLC patient with acquired resistance to osimertinib than in the specimen collected prior to the treatment.

Conclusions: IGF1R activation could occur following treatment with osimertinib in EGFR-mutant NSCLC with T790M mutation, and might be one of the mechanisms underlying osimertinib resistance. Combined treatment of osimertinib and IGF1R inhibitor might be effective in overcoming the acquired resistance to osimertinib induced by IGF1R activation.

Key points
Significant findings of the study: Using osimertinib-resistant cells, we found that IGF1R activation induced by osimertinib treatment in EGFR-mutant NSCLC
with T790M mutation is involved in resistance. Increased phosphorylation of IGF1R was observed in the tumor specimen from an EGFR-mutant NSCLC patient with acquired osimertinib resistance.

**What this study adds:** IGF1R activation might be one of the mechanisms of osimertinib resistance. A combination therapy with osimertinib and an IGF1R inhibitor might be an optimal approach for overcoming the acquired resistance to osimertinib induced by IGF1R activation.

**Methods**

**Cell culture and reagents**

NSCLC cell lines, PC9 (EGFR E746-A750 del) and H1975 (EGFR L858R + T790M), were used in this study. PC9 cells were established at the Tokyo Medical University (Tokyo, Japan), as previously described, and were kindly provided by Dr Kazuto Nishio (Department of Genome Biology, School of Medicine, Kinki University, Osaka). H1975 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). Osimertinib was provided by AstraZeneca UK Ltd., UK. The culture conditions and other reagents are described in Supplementary Materials and Methods.

**Cell proliferation assay**

The WST-8 cell proliferation assay was performed as previously described. Briefly, the cells were seeded in 96-well plates at $1 \times 10^3$ cells/well in quadruplicate. The cells were grown in the absence or presence of osimertinib at various concentrations for 72 hours. The cell viability was assessed by using a Cell Counting Kit-8 (Wako, Japan).

**Western blotting**

The cells were lysed with a buffer containing protease and phosphatase inhibitors (Roche, Basel, Schweiz). Immunoblot
analysis was performed as previously described. The details of the method and antibodies are provided in Supplementary Materials and Methods.

Quantitative real-time PCR
The quantitative polymerase chain reaction (qPCR) conditions and sequences of the primers used for transcript detection are described in Supplementary Materials and Methods.

Phospho-receptor tyrosine kinase array
Phospho-receptor tyrosine kinase array was performed according to manufacturer’s instructions (R&D Systems, Minneapolis, MN). The procedure is explained in detail in Supplementary Materials and Methods.

Whole-exome sequencing
Genomic DNA of each cell line was extracted using a QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). Fragment libraries were created from sheared samples by sonication and target enrichment was performed using the SureSelectXT Human All Exon V6 kit (Agilent, Santa Clara, CA). Captured DNA was amplified followed by solid-phase bridge amplification and paired-end sequencing on an Illumina NovaSeq 6000 System (Illumina, San Diego, CA). Details of the method are provided in Supplementary Materials and Methods.

RNA interference
Short interfering RNAs (siRNAs) targeting IGF1R (Stealth Select RNAi siRNA), the negative control, and lipofectamine RNAiMAX were purchased from Invitrogen (Carlsbad, CA, USA). The procedure is described in detail in Supplementary Materials and Methods.

Immunohistochemistry
We used tumor tissues from an EGFR-mutant NSCLC patient at Juntendo University Hospital, with the patient’s consent, following a protocol that was approved by the Institutional Review Board. Immunohistochemistry for phosphorylated IGF1R and IGFBP3 was carried out as described in Supplementary Materials and Methods.

Statistical analysis
Statistical analyses were performed using GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA). The two-tailed Student’s t-test and ANOVA were used to compare the values. Significant differences between the means were considered statistically significant at \( P < 0.05 \).

Results
Establishment of osimertinib-resistant cells
To investigate the mechanisms of acquired resistance to the third generation EGFR-TKI, osimertinib (AZD9291), we established osimertinib-resistant cells using EGFR-mutant NSCLC cells with T790M mutation. To generate T790M mutation-positive cells, NSCLC cell line PC9 cells, which express EGFR exon 19 deletion mutation (ΔE746-A750), were continuously exposed to a first-generation EGFR-TKI, gefitinib, over six months, and clonal-resistant cells were isolated. These resistant cells exhibited the presence of T790M mutation, and were, therefore, named as PC9/T790M. The PC9/T790M cells were cultured with stepwise escalation of the osimertinib concentration from 150 nmol/L to 1 μmol/L over six months (following the dose-escalation method), and the osimertinib-resistant cells harboring the T790M mutation, thus obtained, were referred to as PC9/T790M/AZDR. We also established osimertinib-resistant cells from the NSCLC cell line, H1975, which expresses the EGFR L858R/T790M mutation, using the high-concentration method. The H1975 cells were cultured with 1 μmol/L of osimertinib over three months, and the resistant cells that were obtained were named as H1975/AZDR.

As shown in Fig 1a,b, the PC9/T790M cells were sensitive to osimertinib. However, the PC9/T790M/AZDR cells were highly resistant to osimertinib, and acquired an approximately 30-fold higher 50% inhibitory dose (IC50) to osimertinib than the PC9/T790M cells. The PC9/T790M/AZDR cells showed cross-resistance to gefitinib (data not shown). The H1975/AZDR cells were also highly resistant to osimertinib (Fig S1a,b).

We next examined the status of EGFR-related molecules in the absence or presence of osimertinib. The cells were either left untreated or were treated with increasing concentrations of osimertinib (0.1–1 μmol/L) for 3 hours. After the treatment, the cells were lysed, and western blot analysis was performed. As shown in Fig 1c, treatment with osimertinib suppressed the level of phosphorylated EGFR in the PC9 parent, PC9/T790M, and in PC9/T790M/AZDR cells, but the level of phosphorylated AKT was not inhibited in PC9/T790M/AZDR cells. The ERK1/2 phosphorylation...
was partially suppressed in the PC9/T790M/AZDR cells by osimertinib treatment.

Whole-exome sequencing of osimertinib-resistant PC9 cells

To identify the potential mechanism of osimertinib resistance, DNA isolated from the PC9 parent, PC9/T790M, PC9/T790M/AZDR, and the H1975 parent, H1975/AZDR cells was subjected to whole-exome sequencing (Table S1). Several genetic mutations not observed in the PC9 parent, PC9/T790M, and H1975 parent, H1975/AZDR cells were subjected to whole-exome sequencing (Table S1). Several genetic mutations not observed in the PC9 parent, PC9/T790M, and H1975 parent, H1975/AZDR cells were observed in PC9/T790M/AZDR (Table S2) and H1975/AZDR (Table S3) cells. However, genetic alterations potentially relevant to third-generation EGFR-TKI resistance, such as acquisition of EGFR C797S or L798I mutation, loss of T790M mutation, amplification of wild-type EGFR or MET, or mutated KRAS, MEK, BRAF, PIK3CA, were not detected in the PC9/T790M/AZDR and H1975/AZDR cells. The EGFR E746-A750 del + T790M mutation was preserved in PC9/T790M/AZDR cells. The EGFR L858R + T790M mutation was also preserved in H1975/AZDR cells.

Activation of IGF1R and loss of IGFBP3 expression in PC9/T790M/AZDR cells

The activation of bypass signaling pathway contributes to acquired resistance to EGFR-TKIs. We analyzed the phosphorylation level of multiple receptor tyrosine kinases (RTKs) in the osimertinib-resistant PC9 cells by using a human phospho-RTK array kit. This phospho-RTK array kit is designed to simultaneously detect the relative phosphorylation of 49 different RTKs as described in Supplementary Materials and Methods. As shown in Fig 2a,b, IGF1R was markedly activated in the PC9/T790M/AZDR cells, whereas this was not found in the PC9 parent and PC9/T790M cells. Any activation of other reported bypass
pathways, such as HER2, MET, and AXL signaling, resulting in the resistance to EGFR-TKIs was not detected in the PC9/T790M/AZDR cells. The IGF1R activation was also observed in the H1975/AZDR cells (Fig S2).

Previous reports have demonstrated that downregulation of the expression of insulin-like growth factor binding protein 3 (IGFBP3) is involved in the activation of the IGF1R pathway leading to EGFR-TKI resistance. To investigate the mechanism of IGF1R activation in PC9/T790M/AZDR cells, we analyzed the expression of IGFBP3 by western blotting. Consistent with the findings of the RTK array, IGF1R was phosphorylated in the PC9/T790M/AZDR cells compared with that in the PC9/T790M cells (Fig 2c,d). Furthermore, the expression of IGFBP3 was downregulated in the PC9/T790M/AZDR cells (Fig 2c,d).

Activation of IGF1R is involved in osimertinib resistance in PC9/T790M/AZDR cells

To examine whether IGF1R activation could contribute to the osimertinib resistance in PC9/T790M/AZDR cells, the IGF1R expression in these cells was silenced by using two different siRNAs (siRNA#1 and #2). The expression of IGF1R was significantly suppressed by both these siRNAs, as detected by western blotting and qPCR analysis (Fig 3a, b). The sensitivity of cells to osimertinib was significantly restored in PC9/T790M/AZDR cells through the silencing of IGF1R (Fig 3c,d). Similar results were obtained in H1975/AZDR cells (Fig S3a-c).

Inhibition of IGF1R activation could overcome osimertinib resistance in PC9/T790M/AZDR cells

To investigate whether IGF1R inhibition could overcome the osimertinib resistance in PC9/T790M/AZDR cells, we used linstinib, a small-molecule inhibitor of IGF1R. The osimertinib treatment suppressed the phosphorylation of EGFR, and partially inhibited the phosphorylation of ERK1/2 in PC9/T790M/AZDR cells (Fig 4a,b). However, AKT phosphorylation was not inhibited by osimertinib alone. Treatment with linstinib suppressed the phosphorylation of IGF1R, but the phosphorylation of AKT was not suppressed by linstinib alone. Notably, the combined treatment with osimertinib and linstinib effectively suppressed AKT phosphorylation in PC9/T790M/AZDR cells (Fig 4a, b). Furthermore, treatment with linstinib significantly restored the sensitivity to osimertinib in PC9/T790M/AZDR cells, when used in combination with osimertinib.
These findings suggest that IGF1R activation is involved in the acquired resistance to osimertinib in PC9/T790M/AZDR cells. Similar results were obtained in H1975/AZDR cells (Fig S4a-c).

Detection of IGF1R phosphorylation in tumor specimen from an EGFR-mutant NSCLC patient with acquired resistance to osimertinib

Finally, we examined the IGF1R phosphorylation in a pair of tumor specimens obtained before EGFR-TKI treatment and after relapse during the osimertinib treatment of an EGFR-mutant NSCLC patient. A 78-year-old female patient was diagnosed with stage IV lung adenocarcinoma harboring the EGFR L858R mutation. Treatment with gefitinib was initiated as the first-line therapy. At six months after initiation of the gefitinib treatment, the axillary lymph node was enlarged. Biopsy of the axillary lymph node tissue was performed, and EGFR T790M mutation detected. Osimertinib treatment was started, but the primary lung tumor relapsed after eight months. We performed computed tomography-guided lung biopsy, and obtained the relapsed tumor tissue after osimertinib treatment. Although axillary lymph node tissue after gefitinib treatment was not available, we tried to examine the IGF1R phosphorylation in tumor specimens obtained before the TKI treatment and after relapse during the osimertinib treatment by immunohistochemistry. The level of phosphorylated IGF1R was higher in the tumor specimen with acquired resistance to osimertinib as compared to that in the specimen collected prior to the treatment (Fig 5). In contrast, the expression of IGFBP3 was decreased after the development of resistance to osimertinib (Fig 5). These findings were consistent with our in vitro results in osimertinib-resistant PC9/T790M/AZDR cells.

Discussion

IGF1R is a transmembrane receptor tyrosine kinase that is responsible for cellular survival and proliferation, and is
expressed in various types of cancer cells, including NSCLC. IGFBP3 is a carrier protein for insulin-like growth factor, and loss of its expression has been shown to induce the activation of IGF1R. It has been reported that increased activation of IGF1R through the loss of IGFBP3 expression is implicated in resistance to first- and second-generation EGFR-TKIs.

In this study, we established PC9/T790M/AZDR cells resistant to a third-generation EGFR-TKI, osimertinib, and found the activation of IGF1R and loss of IGFBP3 expression in PC9/T790M/AZDR cells. Genetic alterations, such as acquisition of EGFR C797S or L798I mutation, amplification of wild-type EGFR or MET, or mutated KRAS, MEK, BRAF, and PIK3CA, were not detected by whole-exome sequencing. The IGF1R activation was also found in osimertinib-resistant H1975/AZDR cells with T790M mutation. The siRNA-mediated silencing of IGF1R, as well as inhibition of IGF1R activation by linsitinib, significantly restored the sensitivity to osimertinib in both PC9/T790M/AZDR and H1975/AZDR cells. Our findings

Figure 4 Alleviation of osimertinib resistance in PC9/T790M/AZDR cells by inhibition of IGF1R activation. (a) PC9/T790M/AZDR cells were left untreated or were treated either with osimertinib (1 μmol/L) or linsitinib (1 μmol/L), or with their combination for three hours. Cell lysates were subjected to western blot analysis for detection of total and phosphorylated EGF (Y-1068), IGF1R, Akt, ERK1/2, and Actin proteins. The results are representative of two independent experiments. (b) Denstometric analysis of each band was done using ImageQuant TL. The bar graph shows the ratio of the band intensities of phospho-AKT and ERK1/2 proteins. (c) Cells were treated with osimertinib at the indicated concentrations or with a combination of osimertinib and linsitinib (1 μmol/L) for 72 hours. The sensitivity to the drugs was determined by WST-8 assay. (d) The bar graph shows the IC50 values of osimertinib for the cells. (→) osimertinib and (→) osimertinib+linsitinib.
suggest that IGF1R activation could be induced by the treatment with osimertinib in EGFR-mutant NSCLC with T790M mutation, and is involved in osimertinib resistance. Recently, Park et al. reported that IGF1R activation was associated with acquired resistance to another third-generation EGFR-TKI, WZ4002, which was accompanied by downregulation of IGFBP3 expression.26 The combined treatment of WZ4002, either with a chemical IGF1R inhibitor or with a ligand-neutralizing monoclonal antibody, led to the restoration of drug sensitivity to WZ4002 in WZ4002-resistant NSCLC cells. Cortot et al. also demonstrated that activation of IGF1R with IGFBP3 loss was involved in the resistance to WZ4002.25 However, IGF1R activation as a mechanism of resistance to osimertinib has not previously been reported. Various third-generation EGFR-TKIs, including WZ4002, osimertinib, rociletinib, olmutinib, and others, have been developed.12,16 WZ4002 is not allowed for use in clinical practice, and osimertinib is the only third-generation inhibitor that is currently approved by the FDA. Therefore, our data for IGF1R activation in osimertinib-resistant cells are important for the clinical practice in cases of EGFR-mutant NSCLC patients, although that in WZ4002-resistant cells has been previously reported for the two above-mentioned studies.

IGF1R activation and loss of IGFBP3 expression have not yet been validated in clinical specimens from NSCLC patients with acquired resistance to the first-, second-, or third-generation EGFR-TKIs. In our study, we selected the EGFR-mutant NSCLC patient who received the tumor biopsy before EGFR-TKI treatment and after relapse to osimertinib therapy. Increased phosphorylation of IGF1R and decreased expression of IGFBP3 were observed by immunohistochemistry in the tumor specimen after acquired resistance to osimertinib as compared to that in the specimen collected prior to the EGFR-TKI treatment. This study is the first to provide the evidence that IGF1R is activated and the IGFBP3 expression is downregulated, using a clinical specimen from an EGFR-mutant NSCLC patient with acquired resistance to osimertinib, although the evidence is based on the analysis of a single patient. The analysis of DNA from tumor tissues and cell-free plasma collected from NSCLC patients by next-generation sequencing identified various mechanisms of acquired resistance to osimertinib. However, the activation of IGF1R is not a genetic event, unlike EGFR C797S mutation or MET amplification, and it will not be easily detected in clinical specimens by NGS analysis. Tissue-based analyses, such as immunohistochemistry, would be necessary to fully characterize the resistance to osimertinib in NSCLC patients.

There are several limitations of this study. First, we did not perform an in vivo animal experiment using a xenograft tumor model of PC9/T790M/AZDR to evaluate the
efficacy of the combined therapy of osimertinib and IGF1R inhibitor. Second, a greater number of tumor specimens from NSCLC patients are required to investigate the significance of IGF1R activation in the acquired resistance to osimertinib. Third, osimertinib is also currently used for the first-line treatment of EGFR-mutant NSCLC patients without T790M. To address the biological significance of IGF1R activation in acquired resistance to osimertinib in this clinical setting, further studies to establish osimertinib-resistant cells from EGFR-mutant NSCLC cells without T790M, such as parental PC9 or HCC827 cells, are necessary. In addition, relapsed tumor tissues from EGFR-mutant NSCLC patients without T790M after first-line treatment with osimertinib are required.

In conclusion, our study suggests that IGF1R activation through the loss of IGFBP3 expression might be one of the mechanisms of osimertinib resistance in EGFR-mutant NSCLC. This study is the first to reveal that the activation of IGF1R conferred acquired resistance to osimertinib in EGFR-mutant NSCLC cells with T790M mutation in a preclinical model, and increased the phosphorylation of IGF1R and decreased the expression of IGFBP3 in the tumor specimen from a patient of EGFR-mutant NSCLC with acquired resistance to osimertinib. Although the small-molecule IGF1R inhibitor is not allowed for use in clinical practice, a combination of osimertinib and IGF1R inhibitor could be an optimal approach for overcoming the acquired resistance to osimertinib in EGFR-mutant NSCLC patients as we observed in this study in osimertinib-resistant cells. However, further studies are necessary in this regard.

Acknowledgments

This work was supported by JSPS KAKENHI Grant Number 15K09230 (Kazuhsa Takahashi), a Grant for Cross-disciplinary Collaboration, and a Grant from the Institute for Environmental & Gender-specific Medicine, Juntendo University. This study was also financially supported in part through grants from the Practical Research for Innovative Cancer Control under Grant Number JP18ck0106252 from the Japan Agency for Medical Research and Development,AMED.

Disclosure

Kazuhsa Takahashi received research funding from Chugai Pharm, Ono Pharma, Taiho Pharm, Nippon Boehringer Ingelheim, AstraZeneca, Pfizer, MSD, and Lilly Japan, outside the submitted work. Fumiuki Takahashi received research funding from AstraZeneca, Nippon Boehringer Ingelheim, MSD, Novartis, and Lilly Japan, outside the submitted work. Ryo Ko received grants and personal fees from Nippon Boehringer Ingelheim; personal fees from AstraZeneca, Taiho Pharmaceutical, Ono Pharmaceutical, Chugai Pharmaceutical, Novartis, and MSD, outside the submitted work. Takehito Shukuya received grants and personal fees from MSD, personal fees from AstraZeneca, Chugai, Eli Lilly, and Ono Pharmaceutical, outside the submitted work. Hiroyuki Mano serves as a board member for CureGene and a scientific advisor for Chugai, and received research funds from Sysmex and Konica-Minolta, outside the submitted work. The remaining authors declare that they have no conflict of interest.

References

1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7–30.
2 Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–57.
3 Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label Randomised Phase 3 Trial. Lancet Oncol 2012; 13: 239–46.
4 Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327–34.
5 Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121–8.
6 Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380–8.
7 Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735–42.
8 Wu YL, Zhou C, Lia T et al. First-line afatinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: Analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 2015; 26: 1883–9.
9 Yu HA, Arcila ME, Rekhtman N et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240–7.
10 Cross DA, Ashton SE, Ghiorgiu S et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046–61.
11 Mok TS, Wu YL, Ahn MJ et al. Osimertinib or platinum-Pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629–40.

148 Thoracic Cancer 11 (2020) 140–149 © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd
12 Murtuza A, Bulbul A. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res 2019; 79: 689–98.
13 Soria JC, Ohe Y, Vansteenkiste J e a. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113–25.
14 Thress KS, Paweletz CP, Felip E e a. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015; 21: 560–2.
15 Chabon JJ, Simmons AD, Lovejoy AF e a. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 2016; 7: 11815.
16 Minari R, Bordi P, Tiseo M. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: Review on emerged mechanisms of resistance. Transl Lung Cancer Res 2016; 5: 695–708.
17 Eberlein CA, Stetson D, Markovets AA e a. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS Signaling in preclinical models. Cancer Res 2015; 75: 2489–500.
18 Nukaga S, Yasuda H, Tsuchihara K e a. Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors. Cancer Res 2017; 77: 2078–89.
19 Planchard D, Loriot Y, Andre F et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol 2015; 26: 2073–8.
20 Ortiz-Cuaran S, Scheffler M, Plenker D e a. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin Cancer Res 2016; 22: 4837–47.
21 Mizuuchi H, Suda K, Murakami I e a. Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. Cancer Sci 2016; 107: 461–8.
22 Minakata K, Takahashi F, Nara T e a. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. Cancer Sci 2012; 103: 1946–54.
23 Guix M, Faber AC, Wang SE e a. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118: 2609–19.
24 Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915–28.
25 Cortot AB, Repellin CE, Shimamura T et al. Resistance to irreversible EGFR receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res 2012; 73: 834–43.
26 Park JH, Choi YJ, Kim SY e a. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGFR receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Oncotarget 2016; 7: 22005–15.

Supporting Information
Additional Supporting Information may be found in the online version of this article at the publisher’s website:
Appendix S1 Supporting information